Overview

This trial is active, not recruiting.

Condition healthy
Treatment duloxetine
Sponsor Rambam Health Care Campus
Start date August 2007
End date August 2009
Trial size 100 participants
Trial identifier NCT00660751, DNIC01CTIL

Summary

The role of central serotonergic and adrenergic systems in the effectiveness of DNIC (Diffuse Noxious Inhibitory Control) will be tested before and after taking Duloxetine and Placebo in a double blind study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model single group assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose basic science
Arm
(Active Comparator)
duloxetine
SNRIs
(Placebo Comparator)
duloxetine
SNRIs

Primary Outcomes

Measure
level of DNIC
time frame: 1 week

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Healthy volunteers - age 18-80 - no chronic disease Exclusion Criteria: - Subjects who suffer from chronic pain / pain syndrome - use of anti-depressant or anti-psychotic drugs - food/ drugs sensitivity - breast feeding

Additional Information

Official title The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control
Principal investigator Prof. David Yarnitsky
Trial information was received from ClinicalTrials.gov and was last updated in April 2008.
Information provided to ClinicalTrials.gov by Rambam Health Care Campus.